Cochrane review: only weak evidence supports tramadol for cancer pain
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Why this matters
- There is only limited, very low quality evidence favoring tramadol (Ultram) for cancer pain.
- There are no studies of tramadol's analgesic effects in children with cancer.
- The Cochrane review concludes that the current place of tramadol as step 2 in the World Health Organization (WHO) analgesic ladder is uncertain.
- The WHO ladder serves as the gold standard for pain management.
- Tramadol is a desirable opioid because of its low risk for abuse.
- Systematic review of 10 randomized controlled trials (n=958 adults) meeting eligibility criteria after a search of the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, and LILACS.
- The most common tramadol doses were 300-400 mg/day.
- Funding: National Institute for He...